Breaking News Instant updates and real-time market news.

JPM

JPMorgan

$100.95

0.36 (0.36%)

, AMZN

Amazon.com

$1,660.55

4.72 (0.29%)

14:02
01/09/19
01/09
14:02
01/09/19
14:02

JPMorgan CEO held dinner for pharma execs, Amazon big topic, CNBC says

JPMorgan Chase (JPM) CEO Jamie Dimon held a private dinner for executives from the pharmaceutical industry on Sunday night ahead of the lender's healthcare conference, CNBC reports. Notably, Amazon (AMZN) was not in attendance, the report says. Roughly 25 industry leaders were present at the dinner, including from companies such as Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ), along with some of JPMorgan's investment bankers, the report says, citing two people with knowledge of the event. The bank's CEO provided some details around what he hopes to accomplish through JPMorgan's health partnership with Amazon and Berkshire Hathaway (BRK.A), the report says. "We are not happy with health-care costs and want to help," Dimon told the room, according to Reuters. Amazon was a major topic at the dinner, as Dimon was asked questions about the ecommerce giant and its ambitions in the health-care market, the report says. Reference Link

JPM

JPMorgan

$100.95

0.36 (0.36%)

AMZN

Amazon.com

$1,660.55

4.72 (0.29%)

LLY

Eli Lilly

$117.50

1.22 (1.05%)

PFE

Pfizer

$43.55

0.1 (0.23%)

JNJ

Johnson & Johnson

$129.46

-0.53 (-0.41%)

BRK.A

Berkshire Hathaway

$295,233.00

743 (0.25%)

BRK.B

Berkshire Hathaway

$196.48

0.24 (0.12%)

  • 09

    Jan

  • 14

    Jan

  • 15

    Jan

  • 15

    Jan

  • 16

    Jan

  • 16

    Jan

  • 22

    Jan

  • 27

    Jan

  • 28

    Jan

  • 29

    Jan

  • 18

    Feb

  • 20

    Feb

  • 26

    Feb

  • 03

    Mar

  • 18

    May

JPM JPMorgan
$100.95

0.36 (0.36%)

01/08/19
MSCO
01/08/19
NO CHANGE
MSCO
Morgan Stanley cuts large cap bank estimates, but says stocks 'still cheap'
Morgan Stanley analyst Betsy Graseck lowered her large cap bank EPS estimates by an average of 3% and cut her target P/E multiples in the group an average of 2% due to her expectations for lower market-based revenues, slower NIM growth, risks to luxury consumer spending in 2019 and the drop in 2018 M&A volumes. Given this, she lowered her price targets by a median 6%, lowering her target for Bank of America (BAC) to $40 from $42, for Citi (C) to $88 from $94 and for JPMorgan (JPM) to $149 from $153. However, as a group she thinks large cap bank stocks still look cheap, as they are largely pricing a recession, which is not her base case. In terms of her top picks, Graseck identifies Bank of America, JPMorgan and State Street (STT).
01/08/19
01/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Unilever (UN, UL) downgraded to Neutral from Buy at UBS. 2. General Dynamics (GD) downgraded to Hold from Buy at Jefferies with analyst Sheila Kahyaoglu saying despite a portfolio of "marquee assets," the company's earnings "lack momentum." 3. Principal Financial (PFG) downgraded to Neutral from Buy at Goldman Sachs with analyst Alex Scott saying he sees less upside in the shares relative to other names in his life insurance coverage universe. 4. JPMorgan (JPM), SunTrust (STI), and U.S. Bancorp (USB) were downgraded to Hold from Buy at Jefferies. 5. Maxar Technologies (MAXR) downgraded to Underperform from Neutral at Credit Suisse, to Sell at Veritas, to Market Perform from Outperform at BMO Capital, and to Sector Perform at National Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/18
12/19/18
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alkermes (ALKS) downgraded to Sell from Neutral at Goldman Sachs with analyst Terence Flynn saying he removed sales of ALKS 5461 for depression from his model as well as the "M&A component" from his price target. He now sees 21% downside to his price target. 2. Analog Devices (ADI) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Craig Hettenbach saying while the company's guidance was "well ahead of peers", he sees it hard to remain positive on the stock considering the ongoing risks to semis in 2019. 3. Under Armour (UA, UAA) downgraded to Underweight from Neutral at Atlantic Equities. 4. Micron (MU) downgraded to Hold from Buy at Needham and to Sector Perform from Outperform at RBC Capital. 5. JPMorgan (JPM) downgraded to Neutral from Overweight at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/19
JEFF
01/08/19
DOWNGRADE
Target $110
JEFF
Hold
JPMorgan downgraded to Hold from Buy at Jefferies
Jefferies analyst Ken Usdin downgraded JPMorgan (JPM) to Hold from Buy and lowered his price target on the stock to $110 from $130, as he believes continued outperformance of the best performer among large cap banks in 2018 "may be more governed" in 2019 as he expects negative EPS revisions and believes that revenues could fall short of consensus expectations for both NII and fees. Among large cap banks, Usdin also downgraded SunTrust (STI) and U.S. Bancorp (USB), both to Hold, this morning.
AMZN Amazon.com
$1,660.55

4.72 (0.29%)

01/09/19
JPMS
01/09/19
NO CHANGE
Target $2100
JPMS
Overweight
Amazon.com named a 2019 best Internet idea at JPMorgan
JPMorgan analyst Doug Anmuth names Amazon.com (AMZN) a best idea for 2019 along with Facebook (FB) and Twitter (TWTR). Amazon shares increased 28% in 2018 but remain well positioned in 2019 as Q1 revenue re-acceleration is likely, Anmuth tells investors in a research note. Further, he sees a "more compelling" valuation following the recent selloff and believes Web Services and advertising will drive 80 basis points of operating margin expansion to 6.0% in 2019. The analyst thinks Amazon will outperform again this year and keeps an Overweight rating on the shares with a $2,100 price target.
01/09/19
MSCO
01/09/19
NO CHANGE
MSCO
Morgan Stanley says Amazon may be near ceiling with current apparel offering
Morgan Stanley analyst Kimberly Greenberger reports that the firm's apparel survey showed that 72% of consumers purchased apparel on Amazon (AMZN) in the past 6 months, up from 69% last year. While this suggests Amazon continues to take apparel market share, the fact that the figure had jumped by 11% from 2016 to 2017 shows its gains may have slowed, said Greenberger, who noted that survey data and analysis suggest this may be due to Amazon seeing less success in fashion apparel versus its traction in apparel basics. Amazon ranked third lowest in terms of perception of offering "fashionable" clothing out of the more than 30 retailers surveyed, with only Walmart (WMT) and Costco (COST) ranked lower, noted Greenberger, who believes a lack of fashion success does not preclude Amazon from becoming the number one apparel market share player but could limit its long-term share gains. The fact that fashion "may be a more difficult code to crack" may also mean that traditional apparel retailers who lead in fashion credibility or low-price can better survive long-term, added the analyst. As previously reported, Greenberger upgraded Urban Outfitters (URBN) to Overweight this morning, in part due to its "fashion authority."
01/09/19
RBCM
01/09/19
INITIATION
Target $122
RBCM
Outperform
PVH Corp initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Tunick initiated PVH (PVH) with an Outperform rating and a price target of $122, citing the company's "strong brands" and Calvin Klein margin recovery. The analyst further notes that since valuation on PVH stock has come in by 4- to 6-times over the past few months, risk reward on the stock has turned more favorable at current levels. Tunick expects the company's best-in-class initiatives to adapt to "new retail" thanks to its Amazon (AMZN) partnerships, social media presence and celebrity collaborations, winning market share and building increased "relevance" with younger consumers.
01/09/19
JEFF
01/09/19
NO CHANGE
JEFF
Jefferies says be selective in Internet, cuts targets on Snap and Facebook
Jefferies analyst Brent Thill this morning cut his price targets on a handful of names in the Internet space. In a research note titled "2019 Playbook," the analyst also downgraded Booking Holdings (BKNG) and Redfin (RDFN) to Hold from Buy. Thill tells investors to selective in the space, and recommends buying Amazon.com (AMZN), Alphabet (GOOGL) and Intuit (INTU) in large cap, Match Group (MTCH), IAC (IAC) and GoDaddy (GDDY) in mid cap, and Wix.com (WIX) and Trade Desk (TTD) in small cap. He expects TripAdvisor (TRIP), Shutterstock (SSTK) and Shutterstock (EIGI) to underperform. Among his price target cuts were Buy-rated Expedia (EXPE) to $150, Buy-rated Facebook to $180, Hold-rated Snap (SNAP) to $7, Hold-rated Sonos (SONO) to $12, Hold-rated Twitter (TWTR) to $33 and Hold-rated Zillow Group (ZG) to $34.
LLY Eli Lilly
$117.50

1.22 (1.05%)

01/07/19
PIPR
01/07/19
NO CHANGE
Target $235
PIPR
Overweight
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
01/08/19
SBSH
01/08/19
DOWNGRADE
Target $235
SBSH
Neutral
Loxo Oncology downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Loxo Oncology (LOXO) to Neutral saying the company is unlikely to receive a competing takeover bid. The analyst raised his price target for the shares to $235 from $201 to reflect the takeover agreement by Eli Lilly (LLY). He believes Mirati Therapeutics (MRTX) is another potential takeover candidate in the oncology space.
12/31/18
CANT
12/31/18
NO CHANGE
Target $53
CANT
Overweight
Doctors impressed by tanezumab data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says that investors she's spoken with are expecting the data for Pfizer (PFE) and Eli Lilly's (LLY) tanezumab in the first half of 2019 to be similar to or worse than what was seen in the first Phase 3 data set reported on October 23. However, physicians are impressed by the data and do not believe the rapidly progressive osteoarthritis imbalance would impact their desire to prescribe tanezumab if it is approved, Chen tells investors in a research note. The analyst believes the safety for tanezumab will be better than expected and that the drug could replace opioids for the treatment of pain. If that is right, peak sales potential of tanezumab could be billions of dollars, and drive upside to modest expectations for the drug, says the analyst. She keeps an Overweight rating on Pfizer with a $53 price target.
12/27/18
ARGS
12/27/18
NO CHANGE
Target $135
ARGS
Buy
Argus sees volume growth, expanded indications as 2019 catalysts for Eli Lilly
Argus analyst David Toung kept his Buy rating and $135 price target on Eli Lilly, saying its 2019 catalysts for upside include anticipated volume growth and expanded indications for existing drugs, along with "potential regulatory approvals". The analyst notes that while the company's mature products are seeing slower sales and face patent expiration and the loss of exclusivity, he also expects Eli Lilly to generate earnings growth from margin expansion. Toung is also confident in 2019 contribution of Eli Lilly's recently launched Olumiant for rheumatoid arthritis, Verzenio for the second-line treatment of breast cancer, and Taltz for active psoriatic arthritis.
PFE Pfizer
$43.55

0.1 (0.23%)

01/03/19
01/03/19
INITIATION

Pfizer initiates Phase 2b/3 clinical trial for PF-06651600
Pfizer announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body, and currently has no approved therapies. Based on the totality of the data and the emerging clinical profile, PF-06651600 was granted Breakthrough Therapy designation from FDA for the treatment of alopecia areata in September 2018. PF-06651600 will also continue to be evaluated for rheumatoid arthritis, Crohn's disease and ulcerative colitis.
12/28/18
BTIG
12/28/18
NO CHANGE
Target $190
BTIG
Buy
Sarepta's recent weakness represents 'buying opportunity', says BTIG
BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta (SRPT), noting that while the stock was among the best performing biotech names this year, its recent weakness represents a "potential buying opportunity". The analyst believes that the company's AAVrh74 micro-dystrophin gene therapy for the treatment of Duchenne Muscular Dystrophy program leads those of Pfizer (PFE) and Solid Biosciences (SLDB) and expects Sarepta to reach about $2B in peak U.S. sales by 2024.
12/27/18
ARGS
12/27/18
NO CHANGE
Target $47
ARGS
Buy
GlaxoSmithKline's high dividend yield 'attractive', says Argus
Argus analyst John Eade kept his Buy rating and $47 price target on GlaxoSmithKline (GSK) with a positive view on its planned joint venture with Pfizer (PFE) combining the companies' consumer businesses. The analyst expects the transaction to boost GlaxoSmithKline shares in the next 2-3 years. Eade also cites the company's 5.2% dividend yield, which he sees as "attractive in a low-interest-rate environment."
JNJ Johnson & Johnson
$129.46

-0.53 (-0.41%)

12/20/18
WELS
12/20/18
NO CHANGE
WELS
Outperform
No change in talc litigation risk for Johnson & Johnson, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that the NY Times reported that Johnson & Johnson has lost its bid to overturn the $4.7B in a talc trial in St. Louis in July 2018. After checking with the company, the analyst is "able to confirm" that the decision relates to the trial judge denying Johnson & Johnson's post trial motion to set aside the $4.7B verdict. Biegelsen understands that the company had to file this motion in order to file its actual appeal of the decision with the appellate court. As such, he believes the judge's decision should not materially affect the overall talc situation for Johnson & Johnson. Wells Fargo has an Outperform rating on the shares.
01/02/19
SBSH
01/02/19
NO CHANGE
SBSH
Citi makes four rating changes in Medical Devices, 'warning up' to J&J
Citi analyst Amit Hazan issued his 2019 preview for Medical Devices, which included four rating changes. The analyst upgraded both Zimmer Biomet (ZBH) and Baxter International (BAX) to Buy from Neutral, downgraded Medtronic (MDT) to Neutral from Buy and downgraded Abbott Laboratories (ABT) to Sell from Neutral. He also kept Buy ratings on Intuitive Surgical (ISRG) and Boston Scientific (BSX), but adds he's "relatively more cautious." Further, Hazan kept a Sell rating on Edwards Lifesciences (EW) and says he's "warming up" to Neutral-rated Johnson & Johnson (JNJ). The analyst expects "fairly stable" fundamentals for the group in 2019, with "modest slowdowns" in organic sales and earnings growth.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."
01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.
BRK.A Berkshire Hathaway
$295,233.00

743 (0.25%)

09/19/18
GDHS
09/19/18
NO CHANGE
GDHS
AutoNation doesn't profile as very good sale candidate, says Gordon Haskett
Gordon Haskett's Event-Driven researcher Don Bilson noted that Berkshire Hathaway's (BRK.A) Warren Buffett previously stated with his purchase of Van Tuyl Group that "this is the beginning of a journey that will have no end." While Berkshire buying AutoNation (AN) would "certainly obviate the need for [Chairman and CEO Mike] Jackson to continue on with his search" for a successor, Bilson said AutoNation "doesn't profile as a very good sale candidate" and "this doesn't set up as a situation where Jackson might sell the company as part of his exit."
11/15/18
11/15/18
NO CHANGE

Morgan Stanley says 13F a 'clear signal' of value Buffett sees in financials
Following the release last night of 13F filings detailing the holdings of large investors, including Berkshire Hathaway (BRK.A), Morgan Stanley analyst Kai Pan noted that the filing from Warren Buffett's Berkshire revealed increased stakes in Bank of America (BAC), U.S. Bancorp (USB) and Goldman Sachs (GS) along with new stakes in JPMorgan (JPM), PNC Financial (PNC) and Travelers (TRV). The analyst sees these investments, along with the fact that Berkshire's s financial holdings stood at 46% of its overall $203B equity portfolio as of quarter end, as a "clear signal" of the value that Buffett sees in financials, Pan tells investors. He adds that he views Buffett's new stake in Oracle (ORCL) as another "notable" new purchase.
10/17/18
JPMS
10/17/18
NO CHANGE
Target $375000
JPMS
Overweight
Berkshire shares are undervalued on look-through earnings, says JPMorgan
JPMorgan analyst Sarah DeWitt views Berkshire Hathaway as one of the best value plays in her coverage group. Although the stock appears more expensive than the S&P 500 at 20 times 2019 estimated earnings, reported earnings ignore the company's "massive" equity portfolio of nearly $200B, DeWitt tells investors in a research note. The analyst thinks a better measure is look-through earnings, which she notes is the one Warren Buffett endorses and includes Berkshire's share of retained earnings of major investees that are not reflected in GAAP earnings. On this basis, Berkshire trades at 13.6 times estimated 2019 look-through earnings, near the all-time historical low for price-to-look-through earnings ratio and a significant discount to the S&P 500 at 16 times, the analyst says. She thinks Berkshire should trade at least in line with the historical median on look-through earnings of 17 times, which would imply 25% upside. The analyst keeps Overweight rating on both of Berkshire's share classes. DeWitt has a $375,000 price target for the class A shares (BRK.A) and $250 target for the class B shares (BRK.B).
10/03/18
BERN
10/03/18
NO CHANGE
BERN
Amazon to be accelerant of disruption coming for healthcare, says Bernstein
Bernstein analyst Lance Wilkes believes disruption is coming for healthcare and that Amazon (AMZN) will be an accelerant of this disruption. Further, the analyst sees a parallel with the fast changes in health insurance which took place in the 90's, when health insurance changed from 90% indemnity to 80% managed care within ten years. Wilkes thinks Amazon is developing a series of business strategies for entering healthcare market segments, namely directly entering online pharmacy, creating a disruptor in the employer healthcare space through its venture with Berkshire (BRK.A) and JPMorgan (JPM), and entering digital consumer healthcare spaces including using Alexa for consumer engagement and behavior modification.
BRK.B Berkshire Hathaway
$196.48

0.24 (0.12%)

TODAY'S FREE FLY STORIES

AAOI

Applied Optoelectronics

$14.62

(0.00%)

07:42
02/22/19
02/22
07:42
02/22/19
07:42
Downgrade
Applied Optoelectronics rating change  »

Applied Optoelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

UCTT

Ultra Clean

$12.59

-0.26 (-2.02%)

07:42
02/22/19
02/22
07:42
02/22/19
07:42
Downgrade
Ultra Clean rating change  »

Ultra Clean downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBM

Cambrex

$40.21

1.935 (5.06%)

, GILD

Gilead

$65.55

-1.43 (-2.14%)

07:41
02/22/19
02/22
07:41
02/22/19
07:41
Downgrade
Cambrex, Gilead rating change  »

Jefferies downgrades…

CBM

Cambrex

$40.21

1.935 (5.06%)

GILD

Gilead

$65.55

-1.43 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CHRA

Charah Solutions

$6.80

0.005 (0.07%)

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Downgrade
Charah Solutions rating change  »

Charah Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONE

CyrusOne

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Downgrade
CyrusOne rating change  »

Jefferies downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 18

    Jun

ARAY

Accuray

$5.26

0.09 (1.74%)

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Hot Stocks
Accuray reports results from SBRT trial »

Accuray announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$64.31

-0.35 (-0.54%)

07:36
02/22/19
02/22
07:36
02/22/19
07:36
Upgrade
Citi rating change  »

Jefferies sees positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Apr

  • 28

    May

  • 13

    Jul

BCLI

BrainStorm

$3.88

0.01 (0.26%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Hot Stocks
BrainStorm announces first U.S.clinical site for Phase 2 MS study »

BrainStorm announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPC

W.P. Carey

$74.39

0.25 (0.34%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Earnings
Breaking Earnings news story on W.P. Carey »

W.P. Carey sees FY19 AFFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

KEYS

Keysight Technologies

$81.74

0.67 (0.83%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Recommendations
Keysight Technologies analyst commentary  »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WFT

Weatherford

$0.78

-0.0436 (-5.32%)

, KR

Kroger

$28.55

-0.2 (-0.70%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

WFT

Weatherford

$0.78

-0.0436 (-5.32%)

KR

Kroger

$28.55

-0.2 (-0.70%)

I

Intelsat

$24.59

0.5 (2.08%)

BSX

Boston Scientific

$40.12

-0.01 (-0.02%)

OAS

Oasis Petroleum

$6.07

-0.28 (-4.41%)

MNST

Monster Beverage

$58.87

0.16 (0.27%)

LKQ

LKQ Corp.

$27.33

0.36 (1.33%)

DK

Delek US

$36.18

-0.8953 (-2.41%)

AGI

Alamos Gold

$4.82

-0.055 (-1.13%)

APEI

American Public Education

$32.93

0.88 (2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 28

    Mar

  • 18

    May

  • 22

    May

  • 28

    May

07:35
02/22/19
02/22
07:35
02/22/19
07:35
General news
Treasury Market Outlook: yields are lower in the U.S. and Europe »

Treasury Market Outlook:…

WPC

W.P. Carey

$74.39

0.25 (0.34%)

07:34
02/22/19
02/22
07:34
02/22/19
07:34
Earnings
W.P. Carey reports Q4 AFFO $1.33, consensus $1.33 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BXG

Bluegreen Vacations

$13.92

-0.12 (-0.85%)

07:34
02/22/19
02/22
07:34
02/22/19
07:34
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TEF

Telefonica

$8.85

0.12 (1.37%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Hot Stocks
EU says Telefonica breached commitment in E-Plus acquisition »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CONE

CyrusOne

$52.44

-4.75 (-8.31%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Recommendations
CyrusOne analyst commentary  »

CyrusOne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 18

    Jun

BIIB

Biogen

$320.99

-14.02 (-4.18%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    May

INSM

Insmed

$25.57

-0.42 (-1.62%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Hot Stocks
Insmed sees FY19 ARIKAYCE revenues $80M-$90M »

Insmed expects cash-based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

OPNT

Opiant Pharmaceuticals

$14.65

-0.25 (-1.68%)

07:32
02/22/19
02/22
07:32
02/22/19
07:32
Recommendations
Opiant Pharmaceuticals analyst commentary  »

Opiant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$418.66

-3.9 (-0.92%)

07:32
02/22/19
02/22
07:32
02/22/19
07:32
Downgrade
Regeneron rating change  »

Regeneron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

  • 11

    Mar

  • 28

    Apr

  • 13

    May

INSM

Insmed

$25.57

-0.42 (-1.62%)

07:31
02/22/19
02/22
07:31
02/22/19
07:31
Earnings
Insmed reports Q4 EPS ($1.19), consensus ($1.06) »

Reports Q4 revenue $9.8M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SHW

Sherwin-Williams

$438.49

0.56 (0.13%)

07:31
02/22/19
02/22
07:31
02/22/19
07:31
Recommendations
Sherwin-Williams analyst commentary  »

Sherwin-Williams price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZGNX

Zogenix

$47.88

0.35 (0.74%)

07:30
02/22/19
02/22
07:30
02/22/19
07:30
Initiation
Zogenix initiated  »

Zogenix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$10.03

-0.07 (-0.69%)

, JNJ

Johnson & Johnson

$135.40

-0.91 (-0.67%)

07:30
02/22/19
02/22
07:30
02/22/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$10.03

-0.07 (-0.69%)

JNJ

Johnson & Johnson

$135.40

-0.91 (-0.67%)

M

Macy's

$24.44

-0.58 (-2.32%)

CZR

Caesars

$9.42

-0.21 (-2.18%)

KEM

Kemet

$18.87

-0.56 (-2.88%)

COUP

Coupa Software

$92.20

-1.55 (-1.65%)

SM

SM Energy

$17.01

-2.69 (-13.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 03

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

ROKU

Roku

$51.47

-2.16 (-4.03%)

07:29
02/22/19
02/22
07:29
02/22/19
07:29
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.